PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PSTV)

CUSIP: 72941H509

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / Common Stock, $0.001 par value per share
Shares outstanding
179,252,507
Total 13F shares
378,108
Share change
-11,053
Total reported value
$131,527
Price per share
$0.35
Number of holders
17
Value change
-$145,825
Number of buys
11
Number of sells
11

Quarterly Holders Quick Answers

What is CUSIP 72941H509?
CUSIP 72941H509 identifies PSTV - PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of PSTV - PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Orin Hirschman
13D/G
3.9%
1,283,681
$410,778 +$231,288 30 Jun 2025
HRT FINANCIAL LP
13F
Company
0.06%
102,065
$96,000 31 Mar 2025
13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP
13F
Company
0.04%
80,505
$76,488 31 Mar 2025
13F
Greg Petersen
3/4/5
Director
mixed-class rows
113,553
mixed-class rows
$66,043 18 Feb 2025
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.03%
57,053
$54,205 31 Mar 2025
13F
Virtu Financial LLC
13F
Company
0.02%
40,030
$38,000 31 Mar 2025
13F
UBS Group AG
13F
Company
0.02%
33,437
$31,765 31 Mar 2025
13F
VANGUARD GROUP INC
13F
Company
0.02%
32,541
$30,914 31 Mar 2025
13F
Ground Swell Capital, LLC
13F
Company
0.01%
13,657
$12,976 31 Mar 2025
13F
TWO SIGMA SECURITIES, LLC
13F
Company
0.01%
13,609
$12,930 31 Mar 2025
13F
Tower Research Capital LLC (TRC)
13F
Company
0%
7,676
$7,293 31 Mar 2025
13F
BlackRock, Inc.
13F
Company
0%
6,960
$6,613 31 Mar 2025
13F
BARCLAYS PLC
13F
Company
0%
1,039
$987 31 Mar 2025
13F
SBI Securities Co., Ltd.
13F
Company
0%
258
$245 31 Mar 2025
13F
CITIGROUP INC
13F
Company
0%
146
$139 31 Mar 2025
13F
OSAIC HOLDINGS, INC.
13F
Company
0%
133
$126 31 Mar 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
50
$48 31 Mar 2025
13F
DANSKE BANK A/S
13F
Company
0%
1
$1 31 Mar 2025
13F
GROUP ONE TRADING LLC
13F
Company
0%
1
$1 31 Mar 2025
13F
Norman D. LaFrance
3/4/5
Chief Medical Officer
class O/S missing
24,073
22 Feb 2024

Institutional Holders of PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PSTV) as of Q2 2025

As of 30 Jun 2025, PLUS THERAPEUTICS, INC. - Common Stock, $0.001 par value per share (PSTV) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 378,108 shares. The largest 10 holders included JANE STREET GROUP, LLC, UBS Group AG, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, MILLENNIUM MANAGEMENT LLC, Ground Swell Capital, LLC, Cubist Systematic Strategies, LLC, BlackRock, Inc., and Tower Research Capital LLC (TRC). This page lists 18 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders
17
Q2 2025 holders
17
Holder diff
0
Investor Q1 2025 Shares Q2 2025 Shares Share Diff Share Chg % Q1 2025 Value $ Q2 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .